Neutralizing antibody response to SARS-CoV-2 variants, as determined by the MSD multiplex assay, following COVID-19 vaccination in cancer patients. - Dukes CW; Whiting J; Mo Q; Cubitt CL; Kuter BJ; Leav B; Kennedy K; Rathwell J; Pilon-Thomas S; Giuliano AR (Vaccine: X, 2025)